Akari Therapeutics

$1.76
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-2.81%) Today
+$0.03 (1.73%) As of 7:29 PM EDT after-hours

Why Robinhood?

You can buy or sell AKTX and other stocks, options, ETFs, and crypto commission-free!

About AKTX

Akari Therapeutics Plc ADR, also called Akari Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. Read More The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Employees
14
Headquarters
London, London & South East
Founded
2004
Market Cap
32.44M
Price-Earnings Ratio
Dividend Yield
Average Volume
4.15M
High Today
$1.83
Low Today
$1.68
Open Price
$1.77
Volume
390.81K
52 Week High
$9.20
52 Week Low
$1.56

Collections

AKTX News

MarketWatchAug 14

Akari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designation

1,243

AKTX Earnings

-$0.66
-$0.44
-$0.22
$0.00
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Sep 26, Pre-Market

More AKTX News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.